Search

Cutaneous squamous cell carcinoma (cSCC) comprises 20% of cases of nonmelanoma skin cancers in the United States. In total, 3% to 5% of squamous cell carcinoma (SCC) are metastatic at the time of presentation, associated with significant mortality due to a lack of standardized treatment options. In total, 95% of these tumors are amenable to the initial standard of treatment, which is surgical resection. However, a small percentage of them require systemic therapy as they are either locally advanced to regional lymph nodes or have distant metastasis. The common sites of presentation of cSCC are the scalp and the face with predictable spread to the intra-parotid, upper jugular, and perifacial lymph nodes. In our case report, however, our patient had a large lump lesion on the upper back, an unusual site of presentation of cSCC, with locally advanced metastasis to the left axillary lymph nodes. Subsequently, the tumor marker study revealed a positive SMARCA4 variant (the essential ATPase subunit of the Switch (SWI)/Sucrose Nonfermenting (SNF) chromatin-remodeling complex) that is even rarer in the context of cSCC. Furthermore, abnormalities in SWI/SNF chromatin-remodeling complex subunits have shown promising results as a target therapy for immune checkpoint inhibitor (ICI) therapy. We present an atypical presentation site of locally advanced rare variant SMARCA4-positive cSCC in a patient who received treatment with chemoradiation and systemic therapy with ICI after primary surgical resection. To date, only 2 cases of SMARCA4-positive cSCC were found in the literature with no details of the treatment received. Our case is unique in its atypical site of presentation as well as showing partial response to radiotherapy (RT) and systemic therapy with ICI.

Introduction and objective Bordetella pertussis is a Gram-negative rod which attacks the respiratory system and causes whooping cough disease. Despite the high percentage of childhood vaccination amongst the population an increasing number of pertussis cases have been observed over time, especially among adolescents and young adults. Objective The aim of the study was to analyze the concentration of IgG anti-PT Bordetella antibodies in the serum of young adults in the aspect of maintaining immunity. Material and methods The study group consisted of 30 patients, medical students aged 21–26 years. They were interviewed with a questionnaire, which asked about their general health, medications taken, basic information about whooping cough, or vaccination status against B. pertussis. The anti-PT Bordetella levels were measured in the collected serum by a commercial ELISA kit (enzyme-linked immunosorbent assay). Results All patients had previously received a mandatory vaccination for pertussis as a child, and 36.6%had received a booster dose after the age of 18. The total average antibody level was 13.977 IU/mL (range: